Creative Medical Technology Holdings, Inc.
CELZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.47 | 0.02 | 0.00 | -0.00 |
| FCF Yield | -155.02% | -125.25% | -187.20% | -38.49% |
| EV / EBITDA | 0.44 | -0.55 | 0.41 | -0.21 |
| Quality | ||||
| ROIC | -90.37% | -54.26% | -63.88% | -23.75% |
| Gross Margin | 60.00% | 60.00% | 67.84% | 45.36% |
| Cash Conversion Ratio | 0.97 | 1.52 | 0.77 | -0.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -50.11% | -53.19% | -18.64% | -19.06% |
| Free Cash Flow Growth | 34.78% | -4.24% | -251.88% | -223.68% |
| Safety | ||||
| Net Debt / EBITDA | 1.05 | 0.62 | 0.82 | -0.45 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -0.73 |
| Efficiency | ||||
| Inventory Turnover | 2.01 | 0.55 | 2.79 | 4.41 |
| Cash Conversion Cycle | -22,508.55 | -31,500.11 | -41,730.04 | -5,706.44 |